Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Arndt Vogel(Princess Margaret Cancer Centre), Erika Martinelli(University of Campania "Luigi Vanvitelli"), Ian Chau(Royal Marsden NHS Foundation Trust), Dirk Arnold(Asklepios Klinik Altona), Josep M. Llovet(Icahn School of Medicine at Mount Sinai), Jens Ricke(LMU Klinikum), Tim Meyer(The Royal Free Hospital), Bruno Daniele(Azienda Ospedaliera G.Rummo), Peter Schirmacher(Heidelberg University), Ulf P. Neumann(RWTH Aachen University), Bruno Sangro(Clinica Universidad de Navarra), Chris Verslype(Universitair Ziekenhuis Leuven), Andrés Cervantes(INCLIVA Health Research Institute), Francis Zech(University of Basel)
Cited by 1,066
Related Papers
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k